Maxim Pharmaceuticals to Close Treatment Protocol and Withdraw NDA for Advanced Malignant Melanoma
Maxim Pharmaceuticals to Close Treatment Protocol and Withdraw NDA for Advanced Malignant Melanoma Results of Phase 3 Clinical Trial for Advanced Malignant Melanoma Presented at 29th ESMO Congress SAN DIEGO, November 1, 2004 - Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced today that based upon the negative outcome of it's confirmatory Phase 3 clinical trial (M0104) studying Ceplene® (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) in advanced malignant melanoma patients with liver metastases, it plans to close the treatment protocol approved by the FDA